Spaulding Clinical Research announced the successful integration and electronic transfer of study data from Spaulding's clinical trial management system (CTMS) to the Medidata Rave electronic data capture (EDC) and clinical data management (CDM) system for a major global pharmaceutical client conducting a Phase I endocrinology indication.
Last June, Spaulding Clinical was recognized by Medidata Solutions as a Medidata Technology Partner after leveraging Medidata Web Services application programming interfaces (APIs) to enable data collected in Spaulding's Phase I unit, including clinical conduct, laboratory, vital signs and ECG data to be automatically transferred into Medidata Rave. Spaulding pioneered the full integration of Medidata Rave Phase I study data demonstrating the efficiency gained from using EDC in a clinical pharmacology environment. The integration enables the rapid transfer of all clinical pharmacology data, including ECG data, into Medidata Rave. Sponsors benefit from Rave data management capabilities for Phase I trials and the ability to more easily view clinical data from all trial phases in Rave.
"The use of the interface on this TQT study delivered flawless data, removed human error, and demonstrated significant cost and time savings," stated Brock Heinz, Vice President of Engineering for Spaulding Clinical.
Using the traditional industry model, manual transcription of the study from the Phase I EDC system delayed study completion by six weeks, increased cost by more than $25,000, and introduced hundreds of transcription errors. In the Spaulding Clinical model, electronic data transfer is completed error-free within minutes of approval to transfer, thus shaving weeks from study timelines.
All study data can be transferred in realtime, or at any defined interval during the normal flow of study conduct, providing sponsors with the latest information at all times.
Spaulding Clinical will be demonstrating their cutting-edge clinical pharmacology and data solutions as well as the new Spaulding iQSM Electrocardiograph and Core ECG Lab Solutions in booth 1905 at the DIA Annual Meeting taking place June 19 – 22, 2011, Chicago, IL.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Patient Engagement Platform Checklist
November 22nd 2024Modern clinical trials are more complex than ever, and one significant reason is the increased focus on patient engagement. Incorporating a patient engagement platform into your clinical trial enhances the patient experience and can lead to more successful trials with stronger, more reliable outcomes. We put together this helpful checklist of key features to look out for when choosing a platform for your study.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.